<DOC>
	<DOCNO>NCT02239393</DOCNO>
	<brief_summary>The mechanism action MSC rely ability modulate pathogenic immune response provide neuroprotection release anti-apoptotic , anti-oxidant trophic factor demonstrate in-vitro in-vivo preclinical study . Patients randomize receive immediate vs. delay treatment either dose equal 1-2 millions/kg body weight autologous MSC , equivalent volume suspension medium baseline . At week 24 treatment reverse . The primary outcome study evaluate : - Treatment 's safety within one year MSC administration measure number , time-frame severity adverse event - Treatment 's activity term reduction total number gadolinium-enhancing lesion ( GEL ) magnetic resonance imaging ( MRI ) scan . Secondary outcomes gain preliminary information efficacy experimental treatment term combine MRI activity clinical efficacy ( incidence relapse disability progression ) .</brief_summary>
	<brief_title>Safety Efficacy Intravenous Autologous Mesenchymal Stem Cells MS : Phase 2 Proof Concept Study</brief_title>
	<detailed_description>The mechanism action Mesenchymal Stem Cells ( MSCs ) rely ability modulate pathogenic immune response provide neuroprotection release anti-apoptotic , anti-oxidant trophic factor demonstrate vitro vivo preclinical study . Patients randomize receive immediate vs. delay treatment either dose equal 1-2 millions/kg body weight autologous MSC , equivalent volume suspension medium baseline . At 6 month treatment reverse . The primary outcome study evaluate - treatment 's safety within one year MSC administration measure number , time-frame severity adverse event - treatment 's activity term reduction total number contrast-gadolinium enhance lesion ( GEL ) magnetic resonance imaging ( MRI ) scan . Secondary outcomes gain preliminary information efficacy experimental treatment term combine MRI activity clinical efficacy ( incidence relapse disability progression ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 ) Males females diagnosis MS 1 . Relapsing remit MS ( RRMS ) respond least 1 year attempt therapy one approved therapy ( betainterferon , glatiramer acetate , natalizumab , mitoxantrone , fingolimod , dimethyl fumarate , teriflunomide , alemtuzumab ) evidence least one following : ) ≥1 clinically document relapse past 12 month ii ) ≥2 clinically document relapse past 24 month iii ) ≥1 gadoliniumenhancing lesion ( GEL ) MRI perform within past 12 month 2 . Secondary progressive MS ( SPMS ) respond least year attempt therapy one approved therapy ( betainterferon , glatiramer acetate , natalizumab , mitoxantrone , fingolimod , dimethylfumarate , teriflunomide , alemtuzumab ) evidence : ) increase ≥1 EDSS point ( randomization EDSS ≤ 5.0 ) 0.5 EDSS point ( randomization EDSS ≥ 5.5 ) past 12 month ii ) ≥1 clinically document relapse ≥ 1 gadoliniumenhancing lesion ( GEL ) MRI within past 12 month 3 . Primary progressive MS ( PPMS ) patient follow feature : ) increase ≥1 EDSS point ( randomization EDSS ≤ 5.0 ) 0.5 EDSS point ( randomization EDSS ≥5.5 ) , past 12 month ii ) ≥ 1 gadoliniumenhancing lesion ( GEL ) MRI perform within past 12 month iii ) positive cerebrospinal fluid ( CSF ) ( oligoclonal banding ) 2 ) Age 18 50 year old , inclusive time inform consent 3 ) Disease duration 2 15 year ( inclusive ) 4 ) EDSS 2.5 6.5 5 ) Able willing sign inform consent prior studyrelated activity 1 ) RRMS fulfil inclusion criterion 2 ) SPMS fulfil inclusion criterion 3 ) PPMS fulfil inclusion criterion 4 ) A history active chronic infection include infection HIV12 , chronic Hepatitis B Hepatitis C 5 ) Treatment immunosuppressive therapy , include natalizumab fingolimod , within 3 month prior randomization 6 ) Previous treatment cladribine alemtuzumab 7 ) Treatment interferonbeta , glatiramer acetate , teriflunomide dimethyl fumarate within 30 day prior randomization ( teriflunomide patient require follow washout either cholestyramine activate charcoal indicated product monograph ) 8 ) Treatment corticosteroid within 30 day prior randomization 9 ) Relapse occur 60 day prior randomization 10 ) Previous history malignancy ( patient report ) basal cell carcinoma skin carcinoma situ remission one year 11 ) Severely limited life expectancy comorbid illness 12 ) History previous diagnosis myelodysplasia previous hematologic disease ( patient report ) current clinically relevant abnormality white blood cell count 13 ) Pregnancy risk pregnancy ( include participant willing practice active contraception duration study ) 14 ) eGFR &lt; 60 mL/min/1.73m2 know renal failure inability undergo MRI examination 15 ) Known allergy gentamicin relate aminoglycosides 16 ) Inability give write informed consent accordance research ethic board guideline 17 ) Concomitant participation another clinical trial 18 ) Inability adhere protocol accord investigator 's medical judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>MSC</keyword>
</DOC>